DOJ supports ruling to strike down ACA, including biosimilars provisions

The FDA's biosimilar pathway would be swept away if the Trump administration's decision to back a court ruling results in striking down the entirety of the Affordable Care Act.

In a letter to the U.S. Court of Appeals for the Fifth Circuit Monday, the U.S. Department of Justice said the court should affirm a December district court ruling which found that when Congress eliminated the ACA's individual mandate in 2017, it rendered the entire law as an unconstitutional overreach...